# MEDA Pharma GmbH & Co. KG clinical trials: 24 (2026)

ClinicalTrials.gov lists 24 trials with MEDA Pharma GmbH & Co. KG as lead sponsor, 0 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by MEDA Pharma GmbH & Co. KG: 24 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/meda-pharma-gmbh-and-co-kg

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2023 | NCT06126952 | Azelastine Allergen Chamber - Onset of Action Study | MEDA Pharma GmbH & Co. KG | Phase 2 | Completed | Seasonal Allergic Rhinitis | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06126952) |
| September 16, 2022 | NCT05544695 | Real-world Evidence Study on Cystistat | MEDA Pharma GmbH & Co. KG | Observational | Completed | Interstitial Cystitis and Bladder Pain Syndrome | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05544695) |
| December 3, 2020 | NCT04652245 | Dymista Allergen Chamber - Onset of Action Study | MEDA Pharma GmbH & Co. KG | Phase 4 | Completed | Seasonal Allergic Rhinitis | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04652245) |
| July 26, 2018 | NCT03599791 | DYmista NAsal Spray in CHInese Patients | MEDA Pharma GmbH & Co. KG | Phase 3 | Completed | Allergic Rhinitis | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03599791) |
| December 28, 2016 | NCT03004131 | MP-AzeFlu Allergen Chamber - Onset of Action Study | MEDA Pharma GmbH & Co. KG | Phase 4 | Completed | Seasonal Allergic Rhinitis | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03004131) |
| October 17, 2011 | NCT01453179 | Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) | MEDA Pharma GmbH & Co. KG | Phase 4 | Completed | Actinic Keratosis | 221 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01453179) |
| April 18, 2011 | NCT01336530 | Tepilta® Versus Oxetacaine, Antacids and Placebo | MEDA Pharma GmbH & Co. KG | Phase 3 | Terminated | Radiation-induced Oesophagitis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01336530) |
| December 8, 2010 | NCT01256086 | Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg | MEDA Pharma GmbH & Co. KG | Phase 2 | Completed | Asthma | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01256086) |
| September 3, 2010 | NCT01194622 | Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two... | MEDA Pharma GmbH & Co. KG | Phase 1 | Completed | Allergic Rhinitis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01194622) |
| August 30, 2010 | NCT01190852 | Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal... | MEDA Pharma GmbH & Co. KG | Phase 1 | Completed | Allergic Rhinitis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01190852) |
| September 15, 2009 | NCT00977483 | Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) | MEDA Pharma GmbH & Co. KG | Phase 3 | Completed | Diabetic Polyneuropathy | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00977483) |
| October 22, 2008 | NCT00777348 | To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol | MEDA Pharma GmbH & Co. KG | Phase 2 | Completed | Asthma, Exercise-Induced | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00777348) |
| October 22, 2008 | NCT00777127 | Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses | MEDA Pharma GmbH & Co. KG | Phase 4 | Completed | Actinic Keratosis | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00777127) |
| September 29, 2008 | NCT00761371 | Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients | MEDA Pharma GmbH & Co. KG | Phase 4 | Completed | Warts | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00761371) |
| December 7, 2006 | NCT00408473 | Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation. | MEDA Pharma GmbH & Co. KG | Phase 4 | Terminated | Atrial Fibrillation | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00408473) |
| May 22, 2006 | NCT00328601 | Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) | MEDA Pharma GmbH & Co. KG | Phase 3 | Completed | Diabetic Polyneuropathy | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00328601) |
| February 22, 2006 | NCT00294320 | Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions | MEDA Pharma GmbH & Co. KG | Phase 3 | Completed | Actinic Keratosis | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00294320) |
| September 19, 2005 | NCT00189319 | To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation | MEDA Pharma GmbH & Co. KG | Phase 4 | Completed | Atrial Fibrillation | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00189319) |
| September 19, 2005 | NCT00189293 | Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts | MEDA Pharma GmbH & Co. KG | Phase 4 | Completed | Genital Warts | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00189293) |
| September 19, 2005 | NCT00189280 | Aldara for the Treatment of Large and/or Multiple sBCC | MEDA Pharma GmbH & Co. KG | Phase 3 | Completed | Carcinoma, Basal Cell | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00189280) |
| September 19, 2005 | NCT00189267 | A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in... | MEDA Pharma GmbH & Co. KG | Phase 2 | Completed | Actinic Keratosis | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00189267) |
| September 19, 2005 | NCT00189254 | A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ | MEDA Pharma GmbH & Co. KG | Observational | Completed | Actinic Keratoses | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00189254) |
| September 19, 2005 | NCT00189241 | A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma | MEDA Pharma GmbH & Co. KG | Phase 3 | Completed | Basal Cell Carcinoma | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00189241) |
| July 18, 2005 | NCT00120523 | 5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis | MEDA Pharma GmbH & Co. KG | Phase 3 | Completed | Atopic Dermatitis | 2,418 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00120523) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 8 |
| Phase 4 | 8 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 22 |
| Terminated | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Keratosis, Actinic | 5 |
| Rhinitis, Allergic, Seasonal | 4 |
| Rhinitis, Allergic | 3 |
| Atrial Fibrillation | 2 |
| Carcinoma, Basal Cell | 2 |
| Diabetic Neuropathies | 2 |
| Cystitis, Interstitial | 1 |
| Dermatitis, Atopic | 1 |
| Asthma, Exercise-Induced | 1 |
| Asthma | 1 |
| Warts | 1 |
| Condylomata Acuminata | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Irish restaurants in the United States](https://specstream.ai/data/businesses/irish-restaurants/united-states)
- [Countertop installers in the United States](https://specstream.ai/data/businesses/countertop-installers/united-states)
- [Wholesale florists in the United States](https://specstream.ai/data/businesses/wholesale-florists/united-states)
- [Pipe suppliers in the United States](https://specstream.ai/data/businesses/pipe-suppliers/united-states)
- [Handyman services in the United States](https://specstream.ai/data/businesses/handyman-services/united-states)
- [Cafes in the United States](https://specstream.ai/data/businesses/cafes/united-states)
